The use of polysomnography (PSG) can aid researchers in further understanding the association between sleep disorders and migraine in children, according to a study published in the Journal of Medicine and Life.
The use of polysomnography (PSG) can aid researchers in further understanding the association between sleep disorders and migraine in children, according to a study published in the Journal of Medicine and Life.
“The relationship between sleep disorders and migraine has been a subject for research, mostly in adults, following initial clinical observations such as sleep deprivation as a trigger for migraine attacks or cessation of migraine attacks after sleep,” according to researchers.
However, sleep plays a vital role in children’s physical, cognitive, and behavioral development, while migraine is a highly complex, multifactorial disorder with no apparent pathophysiology and a highly polymorphic clinical picture in children.
Currently, “a systematic approach to correctly assessing sleep disorders and to trace a link between the intricacies of the pathophysiological mechanisms of migraine and disordered sleep especially in children, is lacking.”
To better understand the relationship between sleep and migraine in children, study participants completed inpatient full-night polysomnographic recordings. Investigators used these recordings to analyze sleep architecture and electroencephalographic patterns.
In this prospective study, 18 patients between the ages of 5 and 17 with a diagnosis of migraine with aura or migraine without aura underwent an overnight PSG recording. The study took place over 28 months. Due to a lack of healthy volunteers, 16 age-matched controls diagnosed with emotional disorders were included in the study.
Researchers collected data on total sleep time (TST), sleep latency, rapid eye movement (REM) latency, sleep efficiency, REM, N1, N2, N3 percentages (% TST), and arousals. Sleep disorder diagnoses were based on sleep efficiency < 89% and REM (% TST) < 17.
In migraineurs, frequency of migraine attacks was similar between patients with migraine with aura and without aura (P = .426).
From the analyzed recordings, researchers found:
N2, N3, and sleep efficiency were similar in both cohorts. Investigators also noted “there was a statistically significant association (P = .041) between the presence of a sleep disorder and migraine. The odds ratio of having a sleep disorder was 5.6 times higher in the migraine group, compared with the control group (odds ratio = 5.60 [0.892], 95% CI, 0.974-32.198, P =.054).”
One limitation of the study is the relatively small number of participants. However, researchers note result analyses were tailored to the small cohorts.
“Broader studies, involving large numbers of children with migraine and healthy volunteers, in different age groups, need to be carried out, in order to better define sleep abnormalities associated with migraine,” authors conclude.
Reference
Nita SA, Teleanu RI, and Bajenaru OA. The role of polysomnography in identifying sleep disorders in children with migraine. J Med Life. 2020;13(1):64-67. doi: 10.25122/jml-2020-0025.
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
Update on Migraine Patient Care Challenges During the Pandemic
October 5th 2021Migraines plague some 35 million Americans, the majority of them women in their 30s and 40s, and disabling pain and symptoms are linked to lost productivity at work, school, and home. On this episode of Managed Care Cast, we bring you an excerpt of an interview with a headache specialist about the extra challenges for patients and providers during the pandemic.
Listen
CGRP Inhibitors: A Promising New Class of Drugs for Migraine
November 14th 2018This fall, The American Journal of Managed Care® convened a panel of experts on migraine to discuss calcitonin gene-related peptide (CGRP) inhibitors, an emerging therapy for the condition, which affects 39 million people in the United States.
Listen